Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Conditions
Interventions
Emricasan (5 mg)
Emricasan (50 mg)
+1 more
Locations
103
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Arizona Clinical and Translational Sciences Research Center
Tucson, Arizona, United States
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Fresno Clinical Research Center
Freestone, California, United States
UCLA The Pfleger Liver Institute
Los Angeles, California, United States
Gastrointestinal Biosciences
Los Angeles, California, United States
Start Date
January 26, 2016
Primary Completion Date
January 29, 2019
Completion Date
February 28, 2019
Last Updated
August 19, 2019
NCT07417553
NCT04469439
NCT07357727
NCT04530383
NCT06154447
NCT07265544
Lead Sponsor
Conatus Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions